// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

PHASE 3 STUDY OF TAFASITAMAB + LENALIDOMIDE AND RITUXIMAB VS PLACEBO + LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL): INMIND

Christian Scholz - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Congestive heart failure

Lenalidomide

THE CORRELATION BETWEEN SKIN RESPONSE AND BLOOD INVOLVEMENT WITH MOGAMULIZUMAB

Pietro Quaglino - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Mogamulizumab

SWATH-MS PROTEOMIC ANALYSIS IDENTIFIES C/EBPΒ SUPPRESSION BY RUNX1-ETO AS A POTENTIAL MEDIATOR OF BLOCK IN DIFFERENTIATION

Aleksandra Azevedo - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

IMPACT OF COVID-19 ON AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN MULTIPLE MYELOMA (MM) PATIENTS: A SINGLE-CENTRE, QUALITATIVE EVALUATION STUDY

Marquita Camilleri - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Multiple Myeloma

N/A

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA ACCORDING TO PRIOR LINES OF TREATMENT AND REFRACTORY STATUS: IKEMA SUBGROUP ANALYSIS

Meletios-Athanasios Dimopoulos - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: IKEMA SUBGROUP ANALYSIS

Ivan Spicka - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

THE EFFECT OF OMECAMTIV MECARBIL IN HOSPITALIZED PATIENTS AS COMPARED WITH OUTPATIENTS: A PRESPECIFIED ANALYSIS OF GALACTIC-HF

Kieran F. Docherty - American College of Cardiology (ACC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

omecamtiv mecarbil (IV)

NEUTROPHIL TO LYMPHOCYTE RATIO FOR TRACKING INFLAMMATION AND RECURRENCE IN PATIENTS WITH RECURRENT PERICARDITIS: POST HOC ASSESSMENT OF A PHASE 3 TRIAL, RHAPSODY

Paul Cremer - American College of Cardiology (ACC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Recurrent pericarditis

Interleukin

REAL-WORLD EXPERIENCE AND UNMET NEEDS IN THE CURRENT MANAGEMENT OF RECURRENT PERICARDITIS: A PHYSICIAN SURVEY AND MEDICAL CHART REVIEW

Ajit B. Raisinghani - American College of Cardiology (ACC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Recurrent pericarditis

N/A

UNDIAGNOSED STAGE 3 CHRONIC KIDNEY DISEASE IN PATIENTS WITH A HISTORY OF HEART FAILURE: A REPORT FROM REVEAL-CKD

Toshiki Moriyama - American College of Cardiology (ACC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

N/A

PREVALENCE AND CHARACTERISTICS OF HEART FAILURE WITH PRESERVED, MILDLY REDUCED, AND REDUCED EJECTION FRACTION IN SPAIN: A RETROSPECTIVE COHORT STUDY USING BIGPAC DATABASE

Mai Duong - American College of Cardiology (ACC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

MEDICAL THERAPY VS. REVASCULARIZATION IN LEFT MAIN CORONARY ARTERY DISEASE WITH PROVEN ISCHEMIA: INSIGHTS FROM THE DEFINE-LM REGISTRY

Takayuki Warisawa - American College of Cardiology (ACC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Left main disease

N/A

COMPARATIVE ANALYSIS OF PERCUTANEOUS REVASCULARIZATION PRACTICE IN THE UNITED STATES AND THE UNITED KINGDOM: INSIGHTS FROM THE BMC2 AND BCIS DATABASES

Brett Wanamaker - American College of Cardiology (ACC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

TICAGRELOR DOES NOT MEDIATE ITS EARLY BENEFICIAL EFFECTS IN ST-ELEVATION MYOCARDIAL INFARCTION BY IMPROVING CORONARY MICROVASCULAR DYSFUNCTION – THE TIMES DOUBLE-BLIND RANDOMISED CONTROLLED TRIAL

Stephen P. Hoole - American College of Cardiology (ACC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myocardial infarction

Clopidogrel bisulfate

CORONARY STENT BALLOON INFLATION TECHNIQUE DURING PERCUTANEOUS CORONARY INTERVENTION IS IMPORTANT IN LIMITING MICROVASCULAR DYSFUNCTION: THE EMPIRE RANDOMISED CONTROLLED TRIAL

Stephen P. Hoole - American College of Cardiology (ACC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Microvascular dysfunction

N/A

REFINING MURRAY’S LAW IN HUMAN EPICARDIAL CORONARY ARTERIES

Daniel Taylor - American College of Cardiology (ACC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

PLASMA DESMOSINE, A BIOMARKER OF ELASTIN DEGRADATION, PREDICTS OUTCOMES IN ACUTE MYOCARDIAL INFARCTION

Kashan Ali - American College of Cardiology (ACC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myocardial infarction

Grace

DERIVATION AND VALIDATION OF A RISK STRATIFICATION TOOL IN PATIENTS WITH TYPE 2 MYOCARDIAL INFARCTION

Caelan Taggart - American College of Cardiology (ACC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Coronary Artery Disease

N/A

CORONARY FLOW RESERVE AND CARDIOVASCULAR OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS

Mihir Kelshiker - American College of Cardiology (ACC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

PHOSPHORYLATION AND FRAGMENTATION PATTERN OF CARDIAC MYOSIN-BINDING PROTEIN C FOR THE DIFFERENTIATION BETWEEN DIFFERENT TYPES OF MYOCARDIAL INJURY

Bashir Alaour - American College of Cardiology (ACC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myocardial injury

Phenylephrine

Copyright © 2026. QuantiNova All rights reserved